|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1999-12-16
|
|
pubmed:abstractText |
The Canadian Burden of Illness Study Group reported that the quality of life (QoL) of multiple sclerosis (MS) patients falls drastically, early in the disease. With disability progression, the physical functioning scales of the Short Form 36 (SF-36) showed further decreases in QoL. The objective of this study is to describe the QoL of MS patients treated with interferon beta-1b (IFNB-1b) and to compare it to the QoL observed in a group of patients who had not been treated with IFNB-1b.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0317-1671
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
276-82
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10563212-Adolescent,
pubmed-meshheading:10563212-Adult,
pubmed-meshheading:10563212-Disability Evaluation,
pubmed-meshheading:10563212-Female,
pubmed-meshheading:10563212-Follow-Up Studies,
pubmed-meshheading:10563212-Health Surveys,
pubmed-meshheading:10563212-Hospitalization,
pubmed-meshheading:10563212-Humans,
pubmed-meshheading:10563212-Interferon-beta,
pubmed-meshheading:10563212-Male,
pubmed-meshheading:10563212-Middle Aged,
pubmed-meshheading:10563212-Multiple Sclerosis,
pubmed-meshheading:10563212-Quality of Life,
pubmed-meshheading:10563212-Retrospective Studies,
pubmed-meshheading:10563212-Severity of Illness Index,
pubmed-meshheading:10563212-Social Class
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Treatment with interferon beta-1b improves quality of life in multiple sclerosis.
|
|
pubmed:affiliation |
MS Clinic, University Hospital, London, ON.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
